Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corp (NQ: INCY )

71.72 +1.33 (+1.89%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corp

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Morning Brief: Top Financial Stories Dominating on Tuesday, June 14
CNBC 
Via Benzinga
Lilly-Incyte Snag FDA Nod For Patchy Hair Loss Treatment — Smaller Rival's Stock Shoots Up In Sympathy
Alopecia areata, an autoimmune disorder that causes patchy hair loss, now has a new treatment that has been approved by the Food and Drug Administration. 
Via Benzinga
Insights On Incyte Corporation
In the first quarter of 2022, Incyte Pharmaeuticals reported very strong quarterly results, highlighted by the launch of Opzelura. The launch continues to perform well, with Q1'22 sales of $13 million... 
Via Talk Markets
Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
From Incyte
Via Business Wire
CHMP Backs Approval of Lilly/Incyte's Olumiant For Patchy Hair Loss
Via Benzinga
4 Analysts Have This to Say About Incyte
Analysts have provided the following ratings for Incyte (NASDAQ:INCY) within the last quarter: 
Via Benzinga
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Stock Market Rally Under Pressure As Walmart, Target Crash On Inflation Woes: Weekly Review
A confirmed market uptrend is reeling as inflation's pain bites. 
Via Investor's Business Daily
Mizuho Sees Relief For This Small-Cap Stock After Patent Legal Overhang Lifted
Via Benzinga
Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas
Key takeaways: Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule The... 
Via Benzinga
Despite Q1 Earnings Miss, Incyte Shares Jump On Revised FY22 Sales Guidance
Via Benzinga
Incyte: Q1 Earnings Insights
Incyte (NASDAQ:INCY) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now
The race is on in eczema treatment as the biggest name faces new rivals. 
Via Investor's Business Daily
FDA Approves Lilly and Incyte's OLUMIANT (baricitinib) for Hospitalized Patients with COVID-19
The U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib) for the treatment of COVID-19 in hospitalized patients. 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
From Incyte
Via Business Wire
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Global Cord Blood Enters Therapy Market Via Cellenkos Acquisition For Over $600M
Global Cord Blood Corporation (NYSE: CO) will acquire Cellenkos Inc and the rights to develop and commercialize all of its existing and future products worldwide. 
Via Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
Via Benzinga
3 Nasdaq Stocks to Buy Now for Growth
These are the best Nasdaq stocks to invest in now. INCY, ROKU and FTXL can make great investments in the rest of the year. 
Via InvestorPlace
Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan
From Incyte
Via Business Wire
EMA's Advisory Committee Backs Approval Of Incyte's Capmatinib In Advanced Lung Cancer Setting
Via Benzinga
Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer
From Incyte
Via Business Wire
How To Attend Incyte Q1 2022 Earnings Conference Call
Incyte (NASDAQ:INCY) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. How to Attend Incyte (INCY) Conference Call Follow this link to access the live... 
Via Benzinga
Incyte to Report First Quarter Financial Results
From Incyte
Via Business Wire
The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
This Favorable Sign Appears On Incyte's Chart
If history is any guide, there may be good fortune ahead for shares of Incyte (NASDAQ:INCY). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the... 
Via Benzinga
Incyte's Ruxolitinib Shows Further Improvement In Facial, Total Body Re-pigmentation At 52 Weeks In Skin Disorder
Incyte Corporation (NASDAQ: INCY)  
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.